Antisense Oligonucleotides Market
According to Intent Market Research, the Antisense Oligonucleotides Market is expected to grow from USD 4.3 billion in 2023 at a CAGR of 15.7% to touch USD 11.8 billion by 2030. The Antisense Oligonucleotides Market is dominated by key players such as Ionis Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals, Biogen Inc., Bristol Myers Squibb, Novartis AG, Exelixis, Inc., Teva Pharmaceutical Industries, Moderna, Inc., Evotec AG, Akcea Therapeutics (A subsidiary of Ionis), Horizon Therapeutics and Wave Life Sciences.